You are here: Industry Insights > Axovant

News List

Axovant, Yposkesi Ink Gene Therapy Pact contractpharma
June 21, 2019
CDMO to support the global development and commercialization of Axovant’s gene therapy programs.
Axovant dumps nelotanserin in retreat from small molecule R&D fiercebiotech
December 28, 2018
Axovant has halted development of nelotanserin after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia.....
Axovant buys more gene therapies, setting it up for a busy 2019 fiercebiotech
December 26, 2018
Axovant has licensed two gene therapies from the University of Massachusetts Medical School (UMMS). The deal accelerates Axovant’s evolution into a gene therapy specialist by....
Axovant axes neuroscience drug, focuses on gene therapies pharmaphorum
December 13, 2018
Swiss biotech Axovant started the year badly, dropping its Alzheimer’s drug intepirdine after it failed in a trial, and it has ended with another flop from a neuroscience drug, nelotanserin.
Axovant Announces Feedback From FDA Meeting Regarding AXO-Lenti-PD for Parkinson’s Disease and Progress in Ongoing SUNRISE-PD Phase 2 Clinical Trial firstwordpharma
December 06, 2018
Axovant Sciences (NASDAQ: AXON), a clinical-stage company developing innovative gene therapies for neurological conditions, today announced feedback from a face-to-face pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding AXO-Lenti-P
Axovant and Benitec estbalish gene therapy partnership pharmaceutical-technology
July 12, 2018
Pharmaceutical company Axovant Sciences has signed a gene therapy licensing and development deal with Australia-based Benitec Biopharma to expand its pipeline of products.
Axovant buys rights for Oxford BioMedica’s Parkinson’s candidate pharmatimes
June 13, 2018
Biopharmaceutical firm Axovant Sciences has agreed exclusive worldwide rights for the development and commercialisation of gene therapy company Oxford BioMedica’s investigational candidate OXB-102, now known as AXO-Lenti-PD, for the treatment of Parkinson
Axovant snatches Teva and Allergan execs to strengthen management pharmafile
June 07, 2018
Axovant has announced reinforcements to its management team with two new additions, snatching up Allergan’s current Chief Medical Officer Dr Gavin Corcoran as its new Executive Vice President of R&D, and Dr Michael Hayden, former Chief Scientific Officer
Axovant shares plummet on dementia drug failure pharmatimes
January 10, 2018
Shares in Axovant Sciences Ltd sank almost 50 percent after investors shrank back on new of the failure of lead drug intepirdine in a mid-stage study in patients with a particular kind of dementia.
Axovant shares capitulate after Alzheimer’s drug failure pharmafile
September 27, 2017
Axovant Sciences was set up with just one drug candidate in its portfolio, and a risky one, at that.